Faron as an investment

Faron Pharmaceuticals (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system.

The Company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Faron has a potential for future value creation and is aiming to enter into a global partnership agreement to commercialize its lead asset bexmarilimab and fund Phase III of the clinical trial.

FARON’S KEY STRENGTHS

1. New and revolutionary therapies for cancer treatment

The company is developing bexmarilimab for the treatment of blood cancers, especially MDS, and solid tumours.

2. Strong scientific base

Faron’s management team consists of top biomedical experts.
Faron has a prestigious and internationally recognized scientific council.
Faron has 23 active patent families.

3. A fast-growing target market with limited competition

The MDS market is a large and growing market that is estimated to reach USD 4.5 billion in 2028.
The company also intends to study the use of bexmarilimab in solid tumours, which would significantly expand the target market.

4. Encouraging bexmarilimab Phase I and II Results

Preliminary phase II results confirmed previous positive results on the efficacy of bexmarilimab against several malignant blood cancers.
The FDA granted bexmarilimab accelerated treatment status for the treatment of r/r MDS.

5. Possibility of future value increase

Faron aims to enter into a global partnership agreement to commercialise bexmarilimab and fund a phase III clinical trial.